Scientific Steering Committee

The Oncology Academy is currently led by a distinguished Scientific Steering Committee.


Dr Matti Aapro, MD

Genolier Cancer Center, Genolier, Switzerland

Dr Aapro is Medical Oncologist and Director at the Genolier Cancer Center, Genolier, Switzerland. From 2010 to 2022, he was President of the European Cancer Organisation (ECO).

Dr Aapro obtained his medical degree from the Faculty of Medicine, University of Geneva, Geneva, Switzerland, and was a Fellow at the Arizona Cancer Center, Tucson, Arizona, USA. Later, he became the founding Chair of the Medical and Radiation Therapy Department at the European Institute of Oncology, Milan, Italy. Presently, Dr Aapro is Executive Board Member of the International Society for Geriatric Oncology (SIOG) and Scientific Advisor to the European School of Oncology (ESO). He is also President of Sharing Progress in Cancer Care (SPCC) and past-President of the Multinational Association for Supportive Care in Cancer (MASCC). Dr Aapro has been a member of the Board of the European Organisation for Research and Treatment of Cancer (EORTC) and the Board of the European Society for Medical Oncology (ESMO).

He is Honorary Editor of Critical Reviews in Oncology/Hematology, Editor of the Journal of Cancer Policy and Founding Editor of the Journal of Geriatric Oncology. Dr Aapro has authored more than 350 publications and his area of interests include new drug development, breast cancer, cancer in the elderly and supportive care.


Prof Karim Fizazi, MD, PhD

Gustave Roussy and the University of Paris-Saclay, Villejuif, France

Prof. Fizazi is a Medical Oncologist at Institute Gustave Roussy, and Professor of Oncology at the University of Paris-Saclay, Villejuif, France. He was head of department of Cancer Medicine at Institute Gustave Roussy from 2005 to 2018 and became Professor at the University of Paris, France in 2009. He is the president of the French Groupe d’Etude des Tumeurs Genito-Urinaires (GETUG).

Prof. Fizazi trained as a medical student at the University of Poitiers, France, before completing his residency (Internat) in Paris. In 1997, he completed a fellowship in medical oncology at Gustave Roussy. After a visiting professorship at the MD Anderson Cancer Center in Houston, TX, USA from 1999 to 2001 where he was working on preclinical models of bone metastases from prostate cancer, he gained his PhD in Molecular Oncology in 2003.

Prof. Fizazi established the Prostate Cancer Consortium in Europe (PEACE) in 2013, to push forward clinical research for prostate cancer in Europe. He is currently leading several large PEACE European academic phase III trials: PEACE-1, PEACE-2 (testing cabazitaxel and pelvic radiotherapy in very high-risk localised prostate cancer, which has completed a 750-patient accrual), and the ongoing PEACE-4 trial, which is testing the role of aspirin and statins in castrate-resistant prostate cancer. The PEACE-6 platform of phase 3 trials aims to test different hypotheses in different subgroups of men with M1 prostate cancer. To date, Prof. Fizazi has chaired six practice-changing trials in the field of genitourinary oncology, including the pivotal denosumab 103 trial, the GETUG 13 trial, the LATITUDE trial, and the TRITON-3 trial.

He is Associate Editor of the European Journal of Cancer. Furthermore, he has authored numerous abstracts at international congresses and has published more than 450 peer-reviewed articles.


Prof Ken Herrmann, MD, MBA

Universitätsklinikum Essen, Essen, Germany and the University of California, Los Angeles, CA, USA

Prof. Dr Herrmann is Professor of Nuclear Medicine at the Universitätsklinikum Essen, Essen, Germany and until recently acted as Adjunct Professor at the Ahmanson Translational Imaging Division of the Department of Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA), Los Angeles, California, USA.

In 2011, he completed his residency in nuclear medicine at Klinikum rechts der Isar, Technische Universität München, Munich, Germany, focusing on his research entitled “In Vivo Proliferation Imaging with 3´deoxy-3´-[18F]Fluorothymidine PET in Oncology”. Following this, Prof. Dr Herrmann then went onto complete a fellowship at Hokkaido University, Hokkaido, Japan, and received an executive MBA degree from the University of Zürich, Zürich, Switzerland. From 2012 to 2016, he served as Vice Chair of the Department of Nuclear Medicine at Universitätsklinikum Würzburg, Würzburg, Germany.

Presently, he is the Chair of the European Association of Nuclear Medicine (EANM) Oncology & Theranostics Committee and Section Editor of The Journal of Nuclear Medicine. He has also authored more 600 peer-reviewed articles.